 BOSTON--BUSINESS WIRE--Verastem, Inc. Nasdaq:VSTM also known as Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical Officer to oversee the Companys clinical and regulatory strategy and Medical Affairs team. Frank brings deep expertise across the full spectrum of clinical and regulatory activities in all stages of Oncology drug dev 